SEROMYCIN SUMMARY
SEROMYCIN®
CYCLOSERINE CAPSULES, USP
Seromycin® (Cycloserine Capsules, USP), 3-isoxazolidinone, 4-amino-, (R)- is a broad- spectrum antibiotic that is produced by a strain of
Streptomyces orchidaceus
and has also been synthesized. Cycloserine is a white to off-white powder that is soluble in water and stable in alkaline solution. It is rapidly destroyed at a neutral or acid pH.
Seromycin is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, Seromycin should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent.
Seromycin may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram-negative bacteria, especially
Enterobacter
spp. and
Escherichia coli.
It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of Seromycin in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.
|
NEWS HIGHLIGHTS
Published Studies Related to Seromycin (Cycloserine)
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder. [2009.10.05]
CONCLUSIONS: This pilot study extends support for the role of d-cycloserine in enhancing therapeutic learning from exposure-based cognitive-behavior therapy and is the first to do so in a protocol emphasizing exposure to feared internal sensations of anxiety in panic disorder.
A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. [2008.03.15]
BACKGROUND: Pilot research has suggested that D-cycloserine (DCS) enhances treatment outcomes for anxiety disorders when employed as an adjunct to exposure therapy (ET). The aim of this study was to determine whether 50 mg of DCS enhances ET for social anxiety disorder (SAD) according to a comprehensive set of symptom and life impairment measures... CONCLUSIONS: This study shows that the administration of DCS before ET enhances treatment outcomes for SAD. Results also provide the first preliminary evidence to suggest that DCS moderates the relationship between a reduction in negative appraisals about one's speech performance and improvement in overall SAD symptoms.
Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. [2008.03]
CONCLUSIONS: These data provide support for the use of d-cycloserine as an augmentation of behavior therapy for OCD and extend findings in animals and other human disorders suggesting that behavior therapy acts by way of long-term potentiation of glutamatergic pathways and that the effects of behavior therapy are potentiated by an NMDA agonist.
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. [2007.10.15]
BACKGROUND: D-cycloserine (DCS), a glutamatergic partial N-methyl-d-aspartate (NMDA) agonist, can facilitate extinction learning related to cued fear in animals and humans. We predicted that DCS would accelerate obsession-related distress reduction in patients with obsessive-compulsive disorder (OCD) undergoing extinction-based exposure therapy... CONCLUSIONS: D-cycloserine augmentation has the potential to increase the efficiency, palatability, and overall effectiveness of standard exposure therapy for OCD.
A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. [2007.09]
Previous research [Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy for social anxiety disorder with d-cycloserine.
Clinical Trials Related to Seromycin (Cycloserine)
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers [Completed]
A total of 20 subjects will participate in this four week, between groups, double-blind,
placebo controlled study. Subjects will participate in two experimental sessions separated by
approximately one week. Subjects will be randomized to receive either 50 mg cycloserine or
placebo combined with cue exposure. Several physiological and subjective outcome measures
(e. g., heart rate, blood pressure, galvanic skin response) will be obtained during the
sessions. Experimental sessions will last approximately 4. 5 hours with follow-up sessions
lasting approximately thirty minutes. Our aims are:
1. To examine the effect of cycloserine vs. placebo on extinction of smoking cue reactivity
in overnight abstinent smokers. Reactivity to smoking cues will be captured with
self-report smoking urges and physiological measures (heart rate, blood pressure, and
skin conductance).
We hypothesize that cycloserine, relative to placebo, will facilitate extinction of
smoking cue reactivity.
2. To examine the effect of cycloserine vs. placebo when combined with two 4. 5 hour
laboratory cue exposure training sessions, on smoking behavior in smokers. Smoking
behavior will be measured with self-report smoking and saliva cotinine levels.
3. To examine the effect of cycloserine vs. placebo on memory performance in nicotine
dependent smokers. Memory performance will be measured with verbal learning, recognition
and recall tasks.
4) To examine the safety and tolerability of cycloserine treatment in smokers. We hypothesize
that cycloserine will be well tolerated by smokers.
Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects [Completed]
Question #1: Will glycine ameliorate cognitive deficits? Hypothesis #1: Based on positive
findings conducted with glycine and milacemide, a glycine prodrug, in schizophrenia and
dementia, we expect that glycine will ameliorate cognitive deficits.
Question #2: Will alcoholic patients show enhanced endocrinal effects to glycine? Hypothesis
#2: Based on the dose-related effects of glycine in healthy subjects, we expect that glycine
will increase the endocrinal response to glycine in alcoholic patients with, supposedly,
dysregulated NMDA receptor function.
Question #3: Will D-cycloserine have ethanol-like effects? Hypothesis #3: If inhibition of
NMDA receptor function is fundamental to the subjective effects of ethanol, then the NMDA
antagonist properties of D-cycloserine should be recognized as ethanol-like (relative to
placebo) in recently detoxified alcoholics and healthy subjects.
Question #4: Will D-cycloserine reverse cognitive benefits of glycine? Hypothesis 4: Based on
the dose related NMDA antagonist activity of D-cycloserine, we expect that D-cycloserine will
compete with the agonist activity of glycine and therefore it will reverse the cognitive
benefits of glycine.
Question #5: Will D-cycloserine inhibit endocrinal effects of glycine? Hypothesis #5: If the
agonist activity of glycine is necessary to determine endocrine response, then the
dose-related NMDA antagonist properties of D-cycloserine should block these effects.
Effects of Weekly Dosing of D-Cycloserine on Cognitive Function in Individuals With Schizophrenia [Completed]
The study aims to assess the effects of single dose and repeated weekly dosing of 50mg
d-cycloserine versus placebo on cognitive and memory functioning in schizophrenia patients.
The study will also examine the effects of 50mg d-cycloserine on positive symptoms and
negative symptoms, as well as assess tolerability and side-effects.
Once Weekly D-cycloserine for Schizophrenia [Recruiting]
This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks
1, 4, & 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic
for 8 weeks in adult outpatients with schizophrenia.
D-Cycloserine in the Management of Chronic Low Back Pain [Not yet recruiting]
Pre-clinical studies in rats suggest that D-cycloserine is effective in the management of
chronic neuropathic pain. This pilot study will attempt to determine the effect of
D-cycloserine in the treatment of neuropathic chronic low back pain. Other aims of this
study are to determine the safety of D-cycloserine in the treatment of neuropathic chronic
low back pain and to determine which pain measurement scales are best at measuring the
efficacy of treatment.
|
